# Zentiva ## Facts | | | |---|---| | Founded | 1488 | | Origin | Czechia | | Headquarters | Prague | | Status | Active | | Previous names | Léčiva a.s. (renamed Zentiva k.s. in 1993) | | Manufacturing | Prague, Czech Republic, Bucharest, Romania, Ankleshwar, India | | Distribution | Pharmacy | | Website | https://www.zentiva.de/ | Zentiva is a pharmaceutical company based in Prague, Czech Republic, that develops, manufactures and markets generic and over-the-counter medicines [9]. Its range covers prescription drugs, non-prescription products and food supplements, and the company says its medicines reach more than 100 million people in over 40 countries across Europe and beyond. It is a medicines maker rather than a cosmetics house, and its consumer-health products are the part of the business closest to everyday personal care. Since April 2026 it has been owned by the Chicago-based private equity firm GTCR, which bought it from Advent International [8]. The company presents itself as the heir to more than five centuries of Prague pharmacy history, tracing its roots to a pharmacy founded in the city in 1488. The name Zentiva is far younger: it was adopted in 1993, and industrial medicine production on the line that leads to today's company began in 1930. Between those dates lie a family business, a factory built by two brothers, decades of state ownership, a stock-market listing and a series of changes of owner. ## Origin & founders Zentiva's own history begins with a pharmacy called At the Black Eagle (U Černého orla in Czech, rendered on the company's German pages as "Zum Schwarzen Adler"). The company describes it as a small business that supplied the people of Prague, and says the pharmacy still exists in the heart of the city. Wikipedia places it in Malá Strana, in the city centre. Whoever opened the pharmacy in 1488 is not named in the company's account. The family that turned the pharmacy into an industrial business arrived more than three centuries later. In 1857 Benjamin Fragner bought At the Black Eagle. His son Karel Fragner took it over in 1886 and, according to Zentiva, built it into the most modern pharmacy in Prague. The decisive step came in the next generation. Jiří Fragner, Karel's youngest son, and his brother Jaroslav, an architect, founded a pharmaceutical production plant named B. Fragner in Dolní Měcholupy. Wikipedia records that the factory, named after Benjamin Fragner, started producing medicines in August 1930. Zentiva marks that year as the beginning of mass production, and it is the point at which the old pharmacy's story becomes the story of a drug manufacturer. Because the company dates its heritage to 1488 while its name dates from 1993, its age depends on how it is counted. Zentiva speaks of a history of more than 530 years and of being a reliable partner in healthcare for that long. Read strictly, 1488 is the founding year of the pharmacy from which the company claims descent, 1930 is the founding year of the factory, and 1993 is the year the business took the name Zentiva [3][9]. This article treats 1488 as the company's heritage date rather than as the founding of a firm called Zentiva. ## History & milestones ### War, nationalisation and the planned economy During the Second World War, according to Wikipedia's account, the Dolní Měcholupy factory served as a refuge for specialists and was the site of early work on isolating penicillin. The war's end brought a break with private ownership. In 1946 B. Fragner was nationalised together with 25 other pharmaceutical companies as part of a broad, state-directed restructuring of the industry. Wikipedia adds that the factory and the original pharmacy were separated at this point, and that the factory became part of SPOFA, then the country's leading pharmaceutical enterprise, with 750 employees. The company's own timeline passes quickly over the following decades and resumes with the fall of the communist regime in 1989, after which, it says, the business went through many changes. ### A new name and a new owner structure In 1993 the company changed its name from Léčiva a.s. to Zentiva k.s. [9]. According to the company, the new name was built as an anagram of the Czech word vítězný, meaning "victorious". Five years later, in 1998, Zentiva's management acquired a majority of the shares and set a new strategic focus on branded generics: copies of medicines whose patents have expired, sold under a brand name rather than only under the name of the active ingredient. That focus drove a decade of regional expansion. In 2003 the company launched the corporate brand Zentiva CZ s.r.o. and bought the Slovak drug maker Slovakofarma. In 2004 its shares were listed on the Prague and London stock exchanges, and Wikipedia notes that the company expanded into Poland, Russia and other markets in Central and Eastern Europe around the same time. The Romanian generics company Sicomed followed in 2005. In 2007, Wikipedia records, Zentiva also acquired Eczacıbaşı Generic Pharmaceuticals [9]; that purchase does not appear on the company's own timeline. ### The Sanofi years In 2008 Zentiva became part of the French pharmaceutical group Sanofi. The company's German-language history describes the event both as a takeover by Sanofi and as a merger with it. Wikipedia describes Zentiva as having become Sanofi's European generics platform. Under Sanofi ownership, Zentiva bought the Swiss company Helvepharm in 2009. ### Carve-out and rapid growth In 2018 Sanofi sold its European generics business, Zentiva, to the private equity firm Advent International. Wikipedia gives the total value of the transaction as €1.919 billion. The company calls this period a carve-out, and it was followed by the fastest run of acquisitions in its history. In 2019, according to Zentiva's timeline, it bought Creo Pharmaceuticals in the United Kingdom, Solacium Pharma in Romania, the Central and Eastern European business of Alvogen, and a production and research site in Ankleshwar, India. Wikipedia dates some of these deals a year later, placing the Alvogen purchase in 2020 and the takeover of the Ankleshwar plant, which it describes as a former Sanofi site, in May 2020 [3][9]. The difference may reflect the gap between when a deal was announced and when it was completed. The geographic push continued. In 2020 Zentiva expanded into the Nordic countries and completed its cardiovascular portfolio in Italy. In 2021 it began operating in Spain and bought three over-the-counter products from the portfolio of ADGC in Germany. The same year it reorganised around a franchise model built on five therapy areas: cardiovascular, consumer health, oncology, respiratory disease and diabetes. It also launched its first biosimilar, a near-copy of a biological medicine, together with the company mAbxience in 21 European countries. Expansion into the Netherlands and Austria followed in 2022. Partnerships became a larger part of the strategy from 2023. That year Zentiva signed a licensing agreement with Adalvo covering respiratory, central nervous system and dermatology products in Europe. In 2025 it acquired a group of heritage brands from Aboca, a move the company says was intended to build up natural consumer-healthcare products across Europe. In the same year it signed a licence and supply agreement with Lupin for a biosimilar of a TNF-alpha inhibitor. In December 2025 Zentiva announced an EU-wide launch of a biosimilar. Zentiva summarises this phase by saying it doubled in size within four years, extended its presence across Europe and came to cover the main therapy areas and standard treatments. ## Ownership Zentiva has changed hands three times since 2008. Sanofi owned it from 2008 until 2018, when Advent International bought it as a carve-out from Sanofi's generics business. On 11 September 2025 the company, Advent and GTCR announced that Advent would sell Zentiva to GTCR. The sale closed on 9 April 2026, according to a press release issued from Chicago and Prague that day [8]. GTCR is a private equity firm founded in 1980 and based in Chicago, with offices in New York and West Palm Beach. Its press release on the deal says the firm has invested in healthcare for about 45 years, including in pharmaceuticals, and that it will back Zentiva's growth through investment in new products, a broader portfolio and wider geographic reach. The firm said it would work with Zentiva's existing leadership, led by chief executive Steffen Saltofte and executive chairperson Kieran Murphy, both of whom it described as having previously worked at healthcare businesses including Acino and GE HealthCare. Sources differ on who the current owner is. Zentiva's own history page and its April 2026 press release name GTCR. The information box on Wikipedia's article about the company still lists Advent International as parent company, although the article's own text reports that GTCR acquired Zentiva in April 2026 [9]. This article follows the more recent, completed transaction and treats GTCR as the owner. Zentiva continues to operate under its own name as a standalone company rather than being merged into another brand. No sister brands under GTCR ownership are documented. ## Philosophy & positioning Zentiva's tagline is "health and wellbeing for all generations", and the company frames almost everything it does around that phrase. It describes its role as contributing to public health in Europe and beyond by developing, producing and supplying high-quality, affordable medicines. Affordability is the core of its positioning: it is a generics business first, and its portfolio sits in pharmacies and medicine cabinets rather than at the beauty counter. The company says it is guided by five core values: accountability, authenticity, collaboration, courage and trust. Each is given a one-line gloss on its website; trust, for example, is defined as always doing the right thing, with integrity. On quality, Zentiva states plainly that quality is "not negotiable" and describes systems for tracking side effects and keeping its products fully traceable. Its sense of its own history is a recurring theme. The company says it is proud of its 530-year heritage and that it wants to act sustainably today so that it can keep providing health and wellbeing for at least another 500 years. It has also set itself the goal of supporting one in five people in Europe with its products by 2028. ## Products & innovation Zentiva describes its offer as a broad range of generic medicines sold under the active-ingredient name, branded generics, specialty products and consumer-healthcare products. In practice this means prescription medicines, over-the-counter products and a wide range of food supplements. The company says it is growing its portfolio in cardiology, circulation, diabetes, oncology, respiratory medicine, the central nervous system and consumer health. The company also highlights what it calls value-added medicines, describing work that manages the life cycle of established active substances and focuses on bioequivalent medicines with added value. It reports having launched more than 140 new products in recent years. Consumer health has become a more visible part of the business. Zentiva says it is strengthening that side of the portfolio through licensing and acquisitions, with particular emphasis on the Czech Republic, Romania and Slovakia. The 2021 purchase of three over-the-counter products in Germany and the 2025 acquisition of heritage brands from Aboca both fit that pattern. The closest link to skin care is dermatology, which appears as one of the therapy areas in the 2023 licensing agreement with Adalvo, and a 2021 milestone the company describes as an innovation in wound healing in the Czech Republic. Biosimilars are the company's newest field. After its first launch with mAbxience in 2021, it added the Lupin agreement in 2025 and an EU-wide biosimilar launch at the end of that year. On manufacturing, Zentiva says it has four production sites and relies on a broad network of external manufacturing partners to secure supply [1]. Wikipedia describes three sites, in Prague, Bucharest and Ankleshwar [9]. The company's own published materials do not name a fourth. ## Sustainability Zentiva organises its sustainability work around three pillars it calls people, partners and planet. Its targets are concrete. The company says its European manufacturing sites run on 100 per cent renewable electricity, and that it has committed to cutting greenhouse gas emissions by 63 per cent by 2034 and by 90 per cent by 2050, targets it reports as validated by the Science Based Targets initiative (SBTi) [6]. It also reports a 25 per cent reduction in the emissions from its own operations and purchased energy since 2021. Under the planet pillar, the company lists decarbonisation, water, waste, pollution prevention and biodiversity as focus areas, aligned with Europe's goal of net-zero emissions by 2050. The people pillar concerns an inclusive workplace; Zentiva reports an employee engagement score of 83 in its 2025 internal survey. Its 2025 sustainability report is prepared in line with the GRI and ESRS reporting standards. ## Recognition Zentiva says it holds a Gold medal from EcoVadis, a company that rates businesses on their sustainability performance; it does not give the year of the rating. Wikipedia records that the company received Top Employer recognition in January 2022 [9]. ## Current status Zentiva is an active, independently operating company. Its most recent change of ownership, the sale from Advent International to GTCR, was completed on 9 April 2026. Its newsroom continued to report business activity in the months before the deal closed, including an EU-wide biosimilar launch in December 2025 and its announced participation in the CPHI Worldwide pharmaceutical trade fair in Frankfurt in October 2025. Figures for the company's size vary by date and source. Zentiva states that it employs more than 5,400 people in over 30 countries. Wikipedia gives 5,143 employees for 2024, and its main text speaks of over 4,700 people across Europe. For 2024, Wikipedia lists revenue of €1.57 billion, operating income of €163.1 million and a net loss of €65.8 million. The company's headquarters remain in Prague. ## Timeline {#belagg-timeline} | Year | Event | Source | |---|---|---| | 1488 | Pharmacy 'Zum Schwarzen Adler' (At the Black Eagle) founded in Prague | https://www.zentiva.de/ueber-uns/geschichte | | 1857 | Benjamin Fragner buys the 'Zum Schwarzen Adler' pharmacy | https://www.zentiva.de/ueber-uns/geschichte | | 1886 | Karel Fragner, Benjamin's son, takes over the pharmacy and develops it into Prague's most modern pharmacy | https://www.zentiva.de/ueber-uns/geschichte | | 1930 | Jiří Fragner and his architect brother Jaroslav found the B. Fragner pharmaceutical production plant in Dolní Měcholupy (start of mass production) | https://www.zentiva.de/ueber-uns/geschichte | | 1946 | B. Fragner nationalised together with 25 other pharmaceutical companies | https://www.zentiva.de/ueber-uns/geschichte | | 1993 | Brand name 'Zentiva' introduced, derived from an anagram of the Czech word 'vítězný' ('victorious') | https://www.zentiva.de/ueber-uns/geschichte | | 1998 | Management acquires majority of shares; new strategic focus on branded generics | https://www.zentiva.de/ueber-uns/geschichte | | 2003 | Acquisition of Slovakofarma (spelled 'Slovakfarma' on the brand's German page) | https://www.zentiva.de/ueber-uns/geschichte | | 2003 | Acquired Slovakofarma (Slovakia) | https://www.zentiva.de/ueber-uns/geschichte | | 2004 | Listed on the Prague and London stock exchanges | https://www.zentiva.de/ueber-uns/geschichte | | 2005 | Acquisition of Romanian generics company Sicomed | https://www.zentiva.de/ueber-uns/geschichte | | 2005 | Acquired Sicomed (Romania) | https://www.zentiva.de/ueber-uns/geschichte | | 2007 | Acquired Eczacıbaşı Generic Pharmaceuticals (Wikipedia only) | https://en.wikipedia.org/wiki/Zentiva | | 2008 | Acquired by / merged with French pharmaceutical company Sanofi | https://www.zentiva.de/ueber-uns/geschichte | ## Awards {#belagg-awards} | Year | Awards | Category | Source | |---|---|---|---| | — | EcoVadis Gold medal | Corporate sustainability rating (self-stated by the brand; year not given) | https://www.zentiva.de/nachhaltigkeit | | 2022 | Top Employer | Employer recognition (January 2022, per Wikipedia) | https://en.wikipedia.org/wiki/Zentiva | ## Sources 1. (T1) https://www.zentiva.de/ 3. (T2) https://www.zentiva.de/ueber-uns/geschichte 6. (T2) https://www.zentiva.de/nachhaltigkeit 8. (T2) https://www.zentiva.com/news/newsroom/2026/2026-04-09-gtcr-completes-acquisition-of-zentiva 9. (T3) https://en.wikipedia.org/wiki/Zentiva --- Glowpedia · · Published 2026-10-06 Please cite with a link to the article URL.